Antibodies to Tat and Vpr in the GRIV cohort: Differential association with maintenance of long-term non-progression status in HIV-1 infection

Biomedicine and Pharmacotherapy

Volumn 57, Issue 1, 2003, Pages 4-14

  Richardson, Max W ^a   Mirchandani, Jyotika ^a   Duong, Joseph ^a   Grimaldo, Sammy ^a   Kocieda, Virginia ^a   Hendel, Houria ^b   Khalili, Kamel ^a   Zagury, Jean François ^b   Rappaport, Jay ^a  

^a TEMPLE UNIVERSITY   (United States)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

GRIV; HIV 1; Non progression; Tat; Vpr

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PROTEIN ANTIBODY; TAT TOXOID; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VPR PROTEIN;

ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CROSS REACTION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENETIC RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOREGULATION; ITALY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; SIMIAN IMMUNODEFICIENCY VIRUS;

COHORT STUDIES; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; GENE PRODUCTS, TAT; GENE PRODUCTS, VPR; HIV ANTIBODIES; HIV LONG-TERM SURVIVORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNOGLOBULIN G; PEPTIDE MAPPING;

EID: 0037228189     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(02)00327-X     Document Type: Article

References (66)

1. Addo M.M., Altfeld M., Rosenberg E.S., Eldridge R.L., Philips M.N., Habeeb K., et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA. 98:2001;1781-1786.
2. Allen T.M., Mortara L., Mothe B.R., Liebl M., Jing P., Calore B., et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol. 76:2002;4108-4112.
3. Allen T.M., O'Connor D.H., Jing P., Dzuris J.L., Mothe B.R., Vogel T.U., et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature. 407:2000;386-390.
4. Altfeld M., Addo M.M., Eldridge R.L., Yu X.G., Thomas S., Khatri A., et al. Vpr is preferentially targeted by CTL during HIV-1 infection. J Immunol. 167:2001;2743-2752.
5. Arya S.K., Guo C., Josephs S.F., Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science. 229:1985;69-73.
6. Ayyavoo V., Muthumani K., Kudchodkar S., Zhang D., Ramanathan P., Dayes N.S., et al. HIV-1 viral protein R compromises cellular immune function in vivo. Int Immunol. 14:2002;13-22.
7. Baier-Bitterlich G., Tretiakova A., Richardson M.W., Khalili K., Jameson B., Rappaport J. Structure and function of HIV-1 and SIV Tat proteins based on carboxy-terminal truncations, chimeric Tat constructs, and NMR modeling. Biomed Pharmacother. 52:1998;421-430.
8. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 415:2002;335-339.
9. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290:2000;486-492.
10. Bartz S.R., Emerman M. Human immunodeficiency virus type I Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J Virol. 73:1999;1956-1963.
11. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nature M. 5:1999;643-650.
12. Dayton A.I., Sodroski J.G., Rosen C.A., Goh W.C., Haseltine W.A. The trans-activator gene of the human T-cell lymphotropic virus type III is required for replication. Cell. 44:1986;941-947.
13. Demirhan I., Chandra A., Mueller F., Mueller H., Biberfeld P., Hasselmayer O., et al. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type I infection and Kaposi's sarcoma. J Human Virol. 3:2000;137-143.
14. Edwards B.H., Bansal A., Sabbaj S., Bakari J., Mulligan M.J., Goepfert P.A. Magnitude of functional CD8+ T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol. 76:2002;2298-2305.
15. Ensoli B., Cafaro A. Control of viral replication and disease onset in cynomolgous monkeys by HIV-1 Tat vaccine. J Biol Reg Homeost Agents. 14:2000;22-26.
16. Feng S., Holland E.C. HIV-1 Tat transactivation requires the loop sequence within TAR. Nature. 334:1988;165-167.
17. de la Fuente C., Santiago F., Deng L., Eadie C., Zilberman I., Kehn K., et al. Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals. BMC Biochem. 3:2002;14-36.
18. Gallimore A., Cranage M., Cook N., Almond N., Bootman J., Rud E. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T-cells in vaccinated macaques. Nature M. 1:1995;1167-1173.
19. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nature M. 1:1996;960-964.
20. Goldstein G., Tribbick G., Manson K. Two B cell eptiopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains. Vaccine. 19:2001;1738-1746.
21. Gringeri A., Santagostino E., Muca-Perja M., Mannucci P.M., Zagury J.F., Bizzini B., et al. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Human Virol. 1:1998;293-298.
22. Gringeri A., Santagostino E., Muca-Perja M., Le Buanec H., Bizzini B., Lachgar A. Tat toxoid as a component of a preventive vaccine in seronegative subjects. J Acquired Immune Deficiency Syndrome Human Retrovirol. 20:1999;371-375.
23. Hel Z., Johnson J., Tryniszewska E., Tsai W., Harrod R., Fullen J., et al. A novel chimeric Rev, Tat and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. Vaccine. 20:2002;3171-3186.
24. Hendel H., Cho Y.Y., Gauthier N., Rappaport J., Schachter F., Zagury J.F. Contribution of cohort studies in understanding HIV pathogenesis: introduction of the GRIV cohort and preliminary results. Biomed Pharmacother. 50:1996;480-487.
25. IAVI Report. 5:(10):2001;1-20.
26. Jeang K.T., Berkhout B., Dropulic B. Effects of integration and replication on transcription of the HIV-1 long terminal repeat. J Biol Chem. 268:1993;24940-24949.
27. Kim D.T., Mitchell D.J., Brockstedt D.G., Fong L., Nolan G.P., Fathman C.G., et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV Tat peptide. J Immunol. 159:1997;1666-1668.
28. Levy D.N., Refaeli Y., MacGregor R.R., Weiner D.B. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 91:1994;10873-10877.
29. Muthumani K., Hwang D.S., Desai B.M., Zhang D., Dayes N.S., Green D.R., et al. HIV-1 induces apoptosis through caspase 9 in T-cells and PBMC's. J Biol Chem. 2002;. [Epub ahead of print].
30. Nagase H., Agematsu K., Kitano K., Takamoto M., Okubo Y., Komiyama A., et al. Mechanism of hypergammaglobulinemia by HIV infection: circulating memory B-cel reduction with plasmacytosis. Clin Immunol. 100:2001;250-259.
31. Notermans D.W., de Jong J.J., Goudsmit J., Bakker M., Roos M.T., Nijholt L., et al. Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses. 17:2001;1003-1008.
32. Opi S., Peloponese J.-M., Esquieu D., Campbell G., de Mareuil J., Walburger A., Tat H.I. V-1 primary and tertiary structures critical to immune response against non-homologous variants. J Biol Chem. 2000;. [Epub ahead of print].
33. Ott M., Emiliani S., Lint C.V., Herbein G., Lovett J., Chirmule N., McCloskey T., et al. Immune hyperactivation of HIV-1-infected T-cells mediated by Tat and the CD28 pathway. Science. 275:1997;1481-1485.
34. Pauza C.D., Trivedi P., Wallace M., Ruckwardt T.J., Le Buanec H., Lu W. Vaccination with Tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA. 97:2000;3515-3519.
35. Ping W., Garber M.E., Fang S.M., Fischer W.H., Jones K.A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:1998;451-462.
36. Popov S., Rexach M., Ratner L., Blobel G., Bukrinsky M. Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem. 273:1998;13347-13352.
37. Rappaport J., Arya S.K., Richardson M.W., Baier-Bitterlich G., Klotman P.E. Inhibition of HIV-1 expression by HIV-2. J Mol M. 73:1995;583-589.
38. Rappaport J., Cho Y.Y., Hendel H., Schwartz E.J., Schachter F., Zagury J.F. 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes. Lancet. 349:1997;922-923.
39. Re M.C., Furlini G., Vignoli M., Ramazzoti E., Roderigo G., De Rosa V., et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J AIDS Human Retrovirol. 10:1995;408-416.
40. Re M.C., Furlini G., Vignoli M., Ramazzotti E., Zauli G., La Placa M. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV. -1-infected hemophiliac patients. Clin Diagnostic Lab Immunol. 3:1996;230-232.
41. Re M.C., Vignoli M., Furlini G., Gibellini D., Colangeli V., Vitone F., et al. Antibodies against full-length Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol. 21:2001;81-89.
42. Reiss P., Lange J.M.A., de Ronde A., de Wolf F., Dekker J., Danner S.A., et al. Antibody response to viral proteins U (vpu) and R (vpr) in HIV-1-infected individuals. J Acquired Immune Deficiency Syndrome. 3:1990a;115-122.
43. Reiss P., Lange J.M.A., de Ronde A., de Wolf F., Dekker J., Debouck C., et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol. 30:1990b;163-168.
44. Richardson M.W., Mirchandani J., Silvera P., Regulier E.G., Capini C., Bojczuk P.M., et al. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoid in rhesus macaques: induction of humoral and cellular immune responses. DNA Cell Biol. 21:2002;637-651.
45. Richardson MW, Sverstiuk A, Gracely EJ, Hendel H, Khalili K, Zagury JF, et al. TREC levels and maintenance of long-term non-progression status in HIV-1 infection. AIDS in press.
46. Richardson M.W., Sverstiuk A., Hendel H., Cheung T.W., Zagury J.F., Rappaport J. Analysis of telomere length and thymic output in fast and slow/non-progressors with HIV infection. Biomed Pharmacother. 54:2000;21-31.
47. Rodman T.C., Lutton J.D., Jiang S., Al-Kouatly H.B., Winston R. Circulating natural IgM antibodies and their corresponding human cord blood cell-derived Mabs specifically combat the Tat protein of HIV. Exp Hematol. 29:2001;1004-1009.
48. Rodman T.C., Sullivan J.J., Bai X., Winston R. The human uniqueness of HIV: innate immunity and the viral Tat protein. Human Immunol. 60:1999;631-639.
49. Rodman T.C., To S.E., Hashish H., Manchester K. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci USA. 90:1993;7719-7723.
50. Sawaya B.E., Khalili K., Gordon J., Srinivasan A., Richardson M., Rappaport J., et al. J Virol. 74:2000;4877-4881.
51. Sawaya B.E., Khalili K., Gordon J., Taube R., Amini S. Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem. 275:2000;35209-35214.
52. Scriba T.J., Treurnicht F.K., Zeier M., Engelbrecht S., van Rensburg E.J. Characterization and phylogenetic analysis of South African HIV-1 subtype C accessory genes. AIDS Res Hum Retroviruses. 17:2001;775-781.
53. Serio D., Rizvi T.A., Cartas M., Kalyanaraman V.S., Weber I.T., Koprowski H., et al. Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci USA. 94:1997;3346-3351.
54. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415:2002;331-335.
55. Silvera P., Richardson M.W., Greenhouse J., Yalley-Ogunro J., Shaw N., Mirchandani J., et al. Outcome of simian-human immunodeficiency virus strain 89.6P challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol. 76:2002;3800-3809.
56. Singh S.P., Tungaturthi P., Cartas M., Tomkowicz B., Rizvi T.A., Khan S.A., et al. Virion-associated HIV-1 Vpr: variable amount in virus particles derived from cells upon virus infection or proviral DNA transfection. Virology. 283:2001;78-83.
57. Truant R., Cullen B.R. The arginine-rich domains present in human immunodeficiency virus type I Tat and Rev function as direct Importin B-dependent nuclear localization signals. Mol Cell Biol. 19:1999;1210-1217.
58. Vanitharani R., Mahalingam S., Rafaeli Y., Singh S.P., Srinivasan A., Weiner D.B., et al. HIV-1 Vpr transactivates LTR-directed expression through sequences present within -278 to -176 and increases virus replication in vitro. Virology. 289:2001;334-342.
59. Viglianti G.A., Mullins J.I. Functional comparison of transactivation by simian immunodeficiency virus from rhesus macaques and human immunodeficiency virus type 1. J Virol. 62:1988;4523-4532.
60. Viscidi R.P., Mayur K., Lederman H.M., Frankel A.D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science. 246:1989;1606-1608.
61. Westendorp M.O., Frank R., Ochsenbauer C., Stricker K., Dhein J., Walczak H., et al. Sensitization of T-cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature. 375:1995;497-500.
62. Wrenger S., Hoffmann T., Faust J., Mrestani-Klaus C., Brandt W., Neubert K., et al. The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T-cell growth. J Biol Chem. 272:1997;30283-30288.
63. Wu Y., Marsh J.W. Selective transcription and modulation of resting T-cell activity by preintegrated HIV DNA. Science. 293:2001;1503-1506.
64. Xiao H., Neuveut C., Tiffany H.L., Benkirane M., Rich E.A., Murphy P.M., et al. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA. 97:2000;11466-11471.
65. Yuan X., Matsuda Z., Matsuda M., Essex M., Lee T.H. Human immunodeficiency virus vpr gene encodes a virion-associated protein. AIDS Res Hum Retroviruses. 6:1990;1265-1271.
66. Zagury J.F., Sill A., Blattner W., Lachgar A., Le Buanec H., Richardson M., et al. Antibodies to the HIV-1 Tat protein correlated with non-progression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Human Virol. 1:1998;282-292.